All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

New Clinical Study Identifies Personalized Treatment Options for Metastatic NSCLC With Plasma Proteome Testing

June 20th 2024

Florida Cancer Specialists & Research Institute spotlights a study uncovering a new testing method to determine personalized care options in NSCLC.

China’s NMPA Grants Priority Review to Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

June 20th 2024

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

European Commission Approves Capivasertib Plus Fulvestrant for ER+ Breast Cancer

June 20th 2024

Capivasertib/fulvestrant was approved in the EU for pretreated, ER-positive, HER2‑negative advanced cancer with 1 or more PIK3CA, AKT1, or PTEN alterations.

DESTINY-Breast Trial Portfolio Spotlights Efficacy of T-DXd in Metastatic Breast Cancer

June 20th 2024

DESTINY-Breast03 and DESTINY-Breast06 showed that T-DXd is a beneficial treatment approach in HER2-positive, -low, and -ultralow metastatic breast cancer.

Liso-Cel Elicits Clinically Meaningful Activity in Heavily Pretreated, Relapsed/Refractory MCL

June 20th 2024

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Zanubrutinib/Rituximab Induction Before Short-Course R-DHAOx Draws Responses in Mantle Cell Lymphoma

June 19th 2024

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Battiwalla Talks Bispecific Antibodies, BTK Inhibitors, and Emerging Therapies in Hematologic Malignancies

June 19th 2024

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.

Emavusertib Monotherapy Shows Antitumor Activity, Safety in Select R/R AML and High-Risk MDS

June 19th 2024

Emavusertib monotherapy was tolerable and produced responses in patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

Advancements in HER2-Directed Therapies Abound for HER2+ Metastatic Breast Cancer

June 19th 2024

Aditya Bardia, MD, MPH, FASCO, discusses the evolving role of T-DXd for patients with HER2-positive advanced breast cancer.

Dana-Farber Researchers Uncover Disparities in Lived Experiences for Patients and Physicians

June 19th 2024

Dana-Farber Cancer Institute investigators have found that people experience discrimination in different ways and in various realms of cancer care.

FDA Places Partial Clinical Holds on 3 Trials Evaluating Azenosertib in Advanced Solid Tumors

June 19th 2024

The FDA placed partial clinical holds on trials evaluating azenosertib in advanced solid tumors, including ovarian cancer and uterine serous carcinoma.

Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

June 19th 2024

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.

The Pursuit of Targeted Agents Broadens the HR+ Breast Cancer Treatment Paradigm

June 19th 2024

Lauren E. Nye, MD, highlights reasons to look beyond CDK4/6 inhibitors when determining treatments for patients with hormone receptor–positive advanced breast cancer and more.

Navigating Neoadjuvant vs Adjuvant Immunotherapy Approaches in NSCLC Requires Further Elucidation

June 19th 2024

Sid Devarakonda, MD, details how new treatment strategies in the neoadjuvant and adjuvant settings are being implemented in the non–small cell lung cancer arena.

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

June 18th 2024

TP53 mutations have an adverse prognostic role in CLL, regardless of 17p deletion status, in the context of chemoimmunotherapy and targeted agents.

Multidisciplinary- and Precision-Based Approaches Enhance Treatment in NSCLC

June 18th 2024

Eric Vallieres, MD, FRCSC, discussed recent advancements in surgical oncology regarding the treatment of patients with non–small cell lung cancer (NSCLC)

Fixed-Duration Glofitamab Yields Responses in R/R Mantle Cell Lymphoma

June 18th 2024

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Ide-Cel Generates Durable Responses in Functionally High-Risk Myeloma

June 18th 2024

Ide-cel induced durable responses and had a favorable risk-benefit profile in patients with functionally high-risk multiple myeloma.

Lucio Gordan, MD Serves on Panel of Oncology Leaders Sharing Insights with Oncology Fellows

June 18th 2024

Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami.

China’s NMPA Gives Go Ahead to Toripalimab Plus Chemotherapy in First-Line ES-SCLC

June 18th 2024

Toripalimab in combination with etoposide and platinum has been approved by the NMPA in China in first-line extensive-stage small cell lung cancer.